An observational study in Sepsis, Sepsis and Septic Shock and Sepsis With Multiple Organ Dysfunction (MOD), sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Shock, Septic with a site in United States — 18 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.
Among the 164 studies in Shock, Septic with a site in United States, this one is the 32nd largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2025, is one of 47 observational ones, reaches primary completion later than 21 of the 25 other live ones, and was the 156th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →18 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Brett A Faine · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 38 · Phase 3 17 · Phase 4 15
First in 1992; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is close to the median of 108 across 408 observational studies indexed under Shock, Septic.
Median enrollment 50 across the 116 interventional studies, 330 across the 47 observational. Of the 110 that completed or were terminated, 47 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 164 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Septic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT07425587Bluejay Diagnostics, Inc.Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study | 2026-12-30 |
| NCT06654895Bluejay Diagnostics, Inc.Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study | 2026-12-31 |
| NCT05011656ExThera Medical CorporationBlood Purification for the Treatment of Pathogen Associated Shock | 2026-12-31 |
| NCT06693726Brett A FaineEarly Angiotensin II in the Emergency Department | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 164 studies in Shock, Septic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:
Participants will have blood drawn from them but will not be subjected to additional interventions.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 116 is close to the median of 108 across 408 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population includes adult patients admitted to the intensive care unit with sepsis with a SOFA score of at least 2. Sepsis is defined by the Sepsis 3 Criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (age 18 and older) admitted to the intensive care unit (ICU) meeting Sepsis 3 Criteria.
Genetic: RNA and DNA Sequencing
Healthy individuals not admitted to the hospital.
Genetic: RNA and DNA Sequencing
DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.
Immune Aging
Time frame: 6 weeks
Mortality (30-day)
Time frame: 30 days
Secondary Infection
Time frame: 30 days
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.
Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →